Results 71 to 80 of about 40,555 (133)

The impact of microsphere deposition algorithm complexity on microdosimetry following Yttrium-90 radioembolization. [PDF]

Biomed Phys Eng Express
Henry EC, Lopez BP, Kappadath SC.
europepmc   +1 more source

Cancer treatment by radioimmunotherapy: insights from a dynamical model of cancer stem cells and hypoxia effects. [PDF]

Sci Rep
Mvogo A, Essongo FE, Hubert Ben-Bolie G.
europepmc   +1 more source

⁹⁰Y Radioactive Microsphere and its In Situ Labeling Strategy in Biological Systems for Real-Time Distribution Visualization after Embolization. [PDF]

Adv Healthc Mater
Lu X, Li Y, Bai H, Zhang Z, Wang X, Li Y, Pang H.   +6 more
europepmc   +1 more source

Post-hoc analysis of adverse events during the EPOCH trial: reconsidering dosimetry. [PDF]

Eur J Nucl Med Mol Imaging
Lam M, Kersting D, Harris W, Boucher E, Garin E, Fowers K, Salem R.   +6 more
europepmc   +1 more source

Role of SIRT in Patients With Hepatocellular Carcinoma: Current Clinical Indications and Future Perspectives. [PDF]

In Vivo
Faggian G, Imbriaco M, Guarino M, Bagni O, Filippi L, Quartuccio N, DE Luca S.   +6 more
europepmc   +1 more source

Intrahepatic cholangiocarcinoma treated with glass yttrium-90 radioembolization: A histopathologic study. [PDF]

Eur J Nucl Med Mol Imaging
Yu Q, Li P, Jain S, Khan A, Steiner J, Liao CY, Franses J, Pillai A, Fung J, Millis JM, Navuluri R, Zangan S, Funaki B, Hart J, Ahmed O, Van Ha T.   +15 more
europepmc   +1 more source

AI-based tumor and organ volumetry predicts early progression after Y-90 radioembolization in liver-dominant metastatic disease. [PDF]

Eur J Nucl Med Mol Imaging
Martinez Heinemann D, Bodden J, Endroes L, Teresa F, Nickel M, Lange S, Mergen M, Spitzl D, Schmid R, Martignoni M, Kirschke J, Eiber M, Braren R, Steinhelfer L.   +13 more
europepmc   +1 more source

Yttrium-90 for the treatment of breast cancer liver metastases: a global propensity-matched study. [PDF]

Proc (Bayl Univ Med Cent)
Miles B, Mallepally A, Oza Q, Moss J.
europepmc   +1 more source

Radioembolization (90Y) achieves higher response rates and reduces progression risk compared with DEB-TACE in hepatocellular carcinoma. [PDF]

Hepatol Commun
Núñez K, Núñez K, Hasani N, Cronan J, Gimenez J, Cohen A, Sandow T, Thevenot P.   +7 more
europepmc   +1 more source

Feasibility of Radioembolization With Yttrium-90 Resin Microspheres Without Lung Shunt Fraction Measurement for Intrahepatic Cholangiocarcinoma. [PDF]

Korean J Radiol
Lee M, Kim DH, Suh M, Paeng JC, Kim HC.
europepmc   +1 more source